<DOC>
	<DOCNO>NCT02896829</DOCNO>
	<brief_summary>It 's observational study base 98 patient include STIM trial extend monitoring patient molecular clinical data , long follow . Are late relapse ? What become patient relapsed STIM trial restart TKI ( inhibitor tyrosine kinase ) treatment ?</brief_summary>
	<brief_title>Follow-up Persistence Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia</brief_title>
	<detailed_description>Chronic myeloid leukemia ( CML ) hematopoietic stem cell disorder ( 9 ; 22 ) ( q34 ; q11 ) reciprocal chromosomal translocation give rise Philadelphia chromosome ( Ph ) generate BCR-ABL1 fusion gene encode constitutively activate protein tyrosine kinase ( PTK ) . Tyrosine kinase Inibitors ( TKIs ) imatinib , block BCR-ABL1 kinase activity , selectively eradicate CML cell induce durable response prolong survival . CML patient treat TKI monitor BCR-ABL1 RT-qPCR ( Reverse Transcription real-time quantitative Polymerase Chain Reaction ) perform peripheral blood sample . A first multicenter study entitle STIM trial demonstrate imatinib could safely discontinue patient complete molecular remission ( CMR ) least 2 year ( undetectable BCR-ABL1 transcript RT-qPCR ) . Around 40 % patient remain prolonged treatment-free remission ( TFR ) treatment cessation . All molecular relapsing patient sensitive imatinib re-challenged . The purpose STIM-FU study follow patient include STIM trial order evaluate molecular status , vital status ongoing treatment patient first molecular relapse . This long term follow allow u predict constant long term control disease possible good define clinical biological CML-related factor predictive molecular relapse TKI discontinuation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>The patient include STIM1 Study CHUBX 2006/06 ( NCT00478985 ) The patient include discharge prematurely STIM1 Study participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>